Published in J Am Coll Cardiol on January 04, 2007
Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation (2010) 2.49
Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol (2010) 2.41
Risk factors for aborted cardiac arrest and sudden cardiac death in children with the congenital long-QT syndrome. Circulation (2008) 2.40
Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals. J Am Coll Cardiol (2011) 2.15
Beta-blocker efficacy in high-risk patients with the congenital long-QT syndrome types 1 and 2: implications for patient management. J Cardiovasc Electrophysiol (2010) 1.99
Mechanisms of cardiac arrhythmias and sudden death in transgenic rabbits with long QT syndrome. J Clin Invest (2008) 1.93
Mutations in cytoplasmic loops of the KCNQ1 channel and the risk of life-threatening events: implications for mutation-specific response to β-blocker therapy in type 1 long-QT syndrome. Circulation (2012) 1.89
Clinical implications for patients with long QT syndrome who experience a cardiac event during infancy. J Am Coll Cardiol (2009) 1.81
QT-interval duration and mortality rate: results from the Third National Health and Nutrition Examination Survey. Arch Intern Med (2011) 1.73
Clinical and genetic determinants of torsade de pointes risk. Circulation (2012) 1.67
Common genetic variants, QT interval, and sudden cardiac death in a Finnish population-based study. Circ Cardiovasc Genet (2011) 1.67
Risk of death in the long QT syndrome when a sibling has died. Heart Rhythm (2008) 1.64
Estradiol promotes sudden cardiac death in transgenic long QT type 2 rabbits while progesterone is protective. Heart Rhythm (2012) 1.62
Electrocardiographic QT interval and mortality: a meta-analysis. Epidemiology (2011) 1.62
Risk factors for recurrent syncope and subsequent fatal or near-fatal events in children and adolescents with long QT syndrome. J Am Coll Cardiol (2011) 1.59
Importance of Knowing the Genotype and the Specific Mutation When Managing Patients with Long QT Syndrome. Circ Arrhythm Electrophysiol (2008) 1.48
Estradiol regulates human QT-interval: acceleration of cardiac repolarization by enhanced KCNH2 membrane trafficking. Eur Heart J (2015) 1.44
Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics. J Gen Physiol (2013) 1.44
Gene-specific paradoxical QT responses during rapid eye movement sleep in women with congenital long QT syndrome. Heart Rhythm (2010) 1.43
Optimal QT interval correction formula in sinus tachycardia for identifying cardiovascular and mortality risk: Findings from the Penn Atrial Fibrillation Free study. Heart Rhythm (2015) 1.41
Genetic testing for inherited cardiac disease. Nat Rev Cardiol (2013) 1.20
Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization. Vasc Health Risk Manag (2010) 1.16
Clinical cardiac safety profile of nilotinib. Haematologica (2012) 1.13
Prevalence and clinical correlates of QT prolongation in patients with hypertrophic cardiomyopathy. Eur Heart J (2011) 1.11
P wave duration is associated with cardiovascular and all-cause mortality outcomes: the National Health and Nutrition Examination Survey. Heart Rhythm (2010) 1.09
Pharmacological approach to the treatment of long and short QT syndromes. Pharmacol Ther (2008) 1.09
Anger, emotion, and arrhythmias: from brain to heart. Front Physiol (2011) 1.06
Potassium-channel mutations and cardiac arrhythmias--diagnosis and therapy. Nat Rev Cardiol (2012) 1.04
A null mutation of the neuronal sodium channel NaV1.6 disrupts action potential propagation and excitation-contraction coupling in the mouse heart. FASEB J (2011) 1.03
Current perspectives in genetic cardiovascular disorders: from basic to clinical aspects. Heart Vessels (2013) 1.02
Genotype- and phenotype-guided management of congenital long QT syndrome. Curr Probl Cardiol (2013) 1.01
Electrocardiographic predictors of adverse cardiovascular events in suspected poisoning. J Med Toxicol (2010) 0.98
Long QT syndrome in patients over 40 years of age: increased risk for LQTS-related cardiac events in patients with coronary disease. Ann Noninvasive Electrocardiol (2008) 0.98
The human ERG1 channel polymorphism, K897T, creates a phosphorylation site that inhibits channel activity. Proc Natl Acad Sci U S A (2008) 0.95
Trigger-specific risk factors and response to therapy in long QT syndrome type 2. Heart Rhythm (2010) 0.94
Risk of cardiac events in patients with asthma and long-QT syndrome treated with beta(2) agonists. Am J Cardiol (2008) 0.93
Congenital long-QT syndromes: a clinical and genetic update from infancy through adulthood. Trends Cardiovasc Med (2008) 0.92
Coffee, alcohol, smoking, physical activity and QT interval duration: results from the Third National Health and Nutrition Examination Survey. PLoS One (2011) 0.92
Age-and sex-dependent mRNA expression of KCNQ1 and HERG in patients with long QT syndrome type 1 and 2. Arch Med Sci (2011) 0.91
Circadian regulation of cardiovascular function: a role for vasoactive intestinal peptide. Am J Physiol Heart Circ Physiol (2010) 0.90
Diastolic transient inward current in long QT syndrome type 3 is caused by Ca2+ overload and inhibited by ranolazine. J Mol Cell Cardiol (2009) 0.90
Origin of complex behaviour of spatially discordant alternans in a transgenic rabbit model of type 2 long QT syndrome. J Physiol (2009) 0.90
A common variant of NOS1AP is associated with QT interval duration in a Chinese population with Type 2 diabetes. Diabet Med (2010) 0.86
Ventricular arrhythmia risk after subarachnoid hemorrhage. Neurocrit Care (2009) 0.86
Long QT syndrome: a Korean single center study. J Korean Med Sci (2013) 0.84
Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes (2014) 0.84
Health status in patients at risk of inherited arrhythmias and sudden unexpected death compared to the general population. BMC Med Genet (2010) 0.83
Acquired Long QT Syndrome Manifesting with Torsades de Pointes in a Patient with Panhypopituitarism due to Radiotherapy. Korean Circ J (2013) 0.83
QT interval prolongation and risk for cardiac events in genotyped LQTS-index children. Eur J Pediatr (2008) 0.83
QT interval abnormalities: risk factors and perioperative management in long QT syndromes and Torsades de Pointes. J Anesth (2013) 0.83
Ventricular repolarization markers for predicting malignant arrhythmias in clinical practice. World J Clin Cases (2015) 0.82
QT Interval in Pregnant and Non-pregnant Women. Emerg (Tehran) (2014) 0.81
Clinical Aspects of Type 3 Long-QT Syndrome: An International Multicenter Study. Circulation (2016) 0.80
Genotype-specific QT correction for heart rate and the risk of life-threatening cardiac events in adolescents with congenital long-QT syndrome. Heart Rhythm (2011) 0.78
Impaired cardiac sympathetic innervation in symptomatic patients with long QT syndrome. Eur J Nucl Med Mol Imaging (2011) 0.78
Ion channel mechanisms related to sudden cardiac death in phenotype-negative long-QT syndrome genotype-phenotype correlations of the KCNQ1(S349W) mutation. J Cardiovasc Electrophysiol (2011) 0.78
Nonalcoholic Fatty Liver Disease Is Associated With QT Prolongation in the General Population. J Am Heart Assoc (2015) 0.78
Nonalcoholic fatty liver disease as a multi-systemic disease. World J Gastroenterol (2016) 0.78
Asymmetry of parental origin in long QT syndrome: preferential maternal transmission of KCNQ1 variants linked to channel dysfunction. Eur J Hum Genet (2015) 0.77
Oral contraceptive use and the risk of cardiac events in patients with long QT syndrome. Heart Rhythm (2014) 0.77
Genetics of inherited primary arrhythmia disorders. Appl Clin Genet (2015) 0.77
How do sex hormones modify arrhythmogenesis in long QT syndrome? Sex hormone effects on arrhythmogenic substrate and triggered activity. Heart Rhythm (2014) 0.76
Risk stratification in electrical cardiomyopathies. Herz (2009) 0.76
Multiscale complexity analysis of the cardiac control identifies asymptomatic and symptomatic patients in long QT syndrome type 1. PLoS One (2014) 0.76
Long QT syndrome: A therapeutic challenge. Ann Pediatr Cardiol (2008) 0.76
Epinephrine-Induced Polymorphic Ventricular Tachycardia in a Patient With Congenital Long QT Syndrome. Korean Circ J (2009) 0.75
Genetic Test for the Channelopaties: Useful or Less Than Useful for Patients? (Part II). Transl Med UniSa (2013) 0.75
Longitudinal Community-Based Study of QT Interval and Mortality in Southeast Asians. PLoS One (2016) 0.75
Never Out of the Woods: Onset of Events in Long QT Syndrome Late in Life Provoked by Atrial Arrhythmias. Indian Pacing Electrophysiol J (2014) 0.75
Presence or Absence of QTc Prolongation in Buprenorphine-Naloxone Among Youth With Opioid Dependence. J Addict Med (2016) 0.75
A case of long QT syndrome: challenges on a bumpy road. Clin Case Rep (2017) 0.75
[Ventricular tachycardia under stress : Characteristic symptom or prognostic relevance?]. Herzschrittmacherther Elektrophysiol (2013) 0.75
Drug-Induced QT Prolongation And Torsades de Pointes. P T (2017) 0.75
[Standard-ECG]. Herzschrittmacherther Elektrophysiol (2008) 0.75
Validation of the Prognostic Utility of the Electrocardiogram for Acute Drug Overdose. J Am Heart Assoc (2017) 0.75
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med (2002) 27.55
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 26.95
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol (2011) 18.34
A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell (2008) 18.18
Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med (2009) 12.44
Universal definition of myocardial infarction. Circulation (2007) 11.69
Subclinical atrial fibrillation and the risk of stroke. N Engl J Med (2012) 11.11
SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med (2011) 11.07
The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA (2013) 10.43
Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nat Biotechnol (2010) 9.01
Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med (2012) 8.84
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61
Chemically derived, ultrasmooth graphene nanoribbon semiconductors. Science (2008) 7.65
Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell (2004) 7.45
Risk stratification in the long-QT syndrome. N Engl J Med (2003) 7.25
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation (2010) 6.71
Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med (2007) 6.47
European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 6.10
Truncations of titin causing dilated cardiomyopathy. N Engl J Med (2012) 6.07
Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation (2002) 5.94
Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J (2006) 5.79
Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters. PLoS Genet (2007) 5.16
An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm (2009) 4.99
Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med (2005) 4.85
Identification of tendon stem/progenitor cells and the role of the extracellular matrix in their niche. Nat Med (2007) 4.80
FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell (2003) 4.68
Narrow graphene nanoribbons from carbon nanotubes. Nature (2009) 4.66
Engineering and algorithm design for an image processing Api: a technical report on ITK--the Insight Toolkit. Stud Health Technol Inform (2002) 4.65
Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol (2008) 4.63
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation (2004) 4.56
Routine versus clinically indicated replacement of peripheral intravenous catheters: a randomised controlled equivalence trial. Lancet (2012) 4.51
Detection of viruses in myocardial tissues by polymerase chain reaction. evidence of adenovirus as a common cause of myocarditis in children and adults. J Am Coll Cardiol (2003) 4.51
Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. Heart Rhythm (2005) 4.21
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol (2013) 4.20
Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A (2007) 4.16
Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria. Eur Heart J (2010) 4.13
Prevalence of long-QT syndrome gene variants in sudden infant death syndrome. Circulation (2007) 4.10
Long QT syndrome. J Am Coll Cardiol (2008) 4.08
Regulatory mutations in transforming growth factor-beta3 gene cause arrhythmogenic right ventricular cardiomyopathy type 1. Cardiovasc Res (2005) 3.99
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation (2003) 3.94
Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med (2014) 3.80
Natural selection on EPAS1 (HIF2alpha) associated with low hemoglobin concentration in Tibetan highlanders. Proc Natl Acad Sci U S A (2010) 3.78
Time dependence of mortality risk and defibrillator benefit after myocardial infarction. Circulation (2004) 3.78
Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation (2008) 3.77
Proposed diagnostic criteria for the Brugada syndrome: consensus report. Circulation (2002) 3.76
A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. Circ Res (2005) 3.75
Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol (2008) 3.73
A multigene predictor of outcome in glioblastoma. Neuro Oncol (2009) 3.57
Clinical characterization of left ventricular noncompaction in children: a relatively common form of cardiomyopathy. Circulation (2003) 3.54
Genetic evaluation of cardiomyopathy--a Heart Failure Society of America practice guideline. J Card Fail (2009) 3.54
Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. JAMA (2005) 3.51
Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J (2004) 3.51